Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC

This article was originally published in The Tan Sheet

Executive Summary

More than 75% of GNC franchisees have accepted firm's proposed class action settlement, supplement retailer announces Oct. 26. Plaintiffs filed motion for final approval Oct. 19; no objections have been voiced yet. Although GNC may terminate deal if more than 10% of its roughly 1,400 franchisees opt out, firm has indicated it will proceed regardless of the final tally. Agreement, which would resolve complaints of wholesale cost overcharges by GNC, awaits approval from Pittsburgh federal Judge Gary Lancaster and would provide each franchisee with wholesale credits on purchases of GNC products in the amount of $125 per store per month for 24 months - approximately $4.2 mil. overall (1"The Tan Sheet" Aug. 20, p. 7)

You may also be interested in...



GNC Franchisee Class Action Settlement Valued At $4.2 Mil.

GNC's more than 1,400 domestic franchisees have until Oct. 11 to decide whether to participate in a class action settlement that ultimately could be worth as much as $4.2 mil.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel